Compounding HRT Solutions for Executive Wellness Hormone Program Patients

According to NIH MedlinePlus and NAMS (The Menopause Society), fatigue and low energy during hormonal transitions may present as a persistent, heavy tiredness that is not relieved by rest, with mornings feeling especially sluggish and afternoons associated with notable drops in alertness. Mental fog, slowed thinking, reduced concentration, diminished stamina for routine tasks, increased need for rest, muscle heaviness, and social withdrawal are commonly associated with hormonal shifts that may alter energy metabolism and mood regulation. Patients experiencing severe or worsening fatigue — particularly when accompanied by unexplained weight change, markedly abnormal mood, or other systemic symptoms — should seek evaluation from a qualified clinician, as these presentations may indicate an underlying medical condition requiring diagnosis and management.

According to NIH MedlinePlus and NAMS (The Menopause Society), brain fog or difficulty concentrating during hormonal transitions may present as impaired working memory, reduced processing speed, word-finding difficulty, and diminished ability to sustain attention on complex tasks. These cognitive symptoms are commonly associated with estrogen fluctuations and sleep disruption that frequently accompany perimenopause and menopause. Patients who experience sudden or severe changes in cognition, confusion, or marked difficulty with orientation should seek prompt evaluation from a qualified clinician, as such presentations may indicate conditions requiring urgent medical assessment.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, persistent reduction in motivation and goal-directed effort may present as slowed task initiation, diminished follow-through, and a sense that routine responsibilities feel disproportionately burdensome. Work output may decrease, prioritization may become difficult, and sustained concentration and planning may require noticeably greater effort. These features are commonly associated with hormonal changes affecting dopaminergic and adrenergic tone during midlife hormonal transitions. Patients experiencing marked or prolonged changes in motivation, especially when accompanied by depressed mood or significant functional impairment, should seek evaluation from a qualified clinician, as these symptoms may indicate a condition requiring diagnosis and treatment.

According to NIH MedlinePlus and NAMS (The Menopause Society), increased stress reactivity or a feeling of being overwhelmed may present as persistent inner tension, racing thoughts, and reduced tolerance for ordinary demands during hormonal transitions. Tasks may feel magnified in scope, decision-making may stall, and mental energy may deplete more rapidly than expected. Heightened irritability, difficulty concentrating, disturbed sleep, and subtle physical signs such as chest tightness or shallow breathing are commonly associated with amplified stress reactivity linked to hormonal fluctuations. Patients who experience sudden severe symptoms — including severe chest pain, difficulty breathing, or an acute change in mental status — should seek urgent medical attention, as such symptoms may indicate a serious medical condition unrelated to hormonal changes.

According to the FDA-approved prescribing information for estradiol transdermal patch, estradiol transdermal patch is an estrogen hormone indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, the treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy associated with menopause, and the prevention of postmenopausal osteoporosis. The labeling describes the patch as delivering estradiol continuously through the skin, bypassing first-pass hepatic metabolism. Per the labeling, the most serious risks associated with estrogen therapy include endometrial cancer (in women with an intact uterus who are not also taking a progestogen), cardiovascular events, venous thromboembolic events, and breast cancer; these risks may vary by age, health status, and duration of use and should be evaluated by the prescribing clinician. Any compounded preparation involving estradiol is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available estradiol transdermal products are separately regulated, and clinical decisions about their use belong with the prescribing clinician.

According to the FDA-approved prescribing information for DHEA (prasterone; Intrarosa), the FDA-approved form of DHEA as prasterone is a vaginal insert indicated for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. The labeling describes prasterone as an endogenous adrenal steroid that acts as a precursor converted locally to estrogens and androgens within vaginal tissue. Per the labeling, systemic hormone levels may rise modestly with use and the clinical significance in patients with hormone-sensitive conditions should be evaluated by the prescribing clinician. Oral DHEA supplements and other compounded DHEA preparations are not FDA-approved drug products and are not reviewed by FDA for safety or effectiveness before dispensing. Commercially available prasterone (Intrarosa) is separately regulated, and clinical decisions about DHEA use in any form belong with the prescribing clinician.